KabaFusion Acquires Infusion Care/Pharmacy Assets from Coram® to Expand its Nationwide Footprint of Patient-Focused Services 

 Expansion to Nearly Double KabaFusion’s Footprint of Specialty Pharmacies Across 25 States 

 CERRITOS, Calif. – August 31, 2022 – KabaFusion, a leading provider of home infusion therapies, today announced it will expand its nationwide footprint by opening infusion care pharmacies in locations recently acquired from Coram Infusion Services (Coram). The transaction expands KabaFusion’s ability to serve a growing number of patients nationwide and strengthens its commitment to deliver high-quality patient care across a broad range of home infusion therapies. 

 “Our expansion will enable KabaFusion to serve a greater number of patients with superior care and home infusion therapies,” said Dr. Sohail Masood, founder and Chief Executive Officer of KabaFusion. “Patient demand for home infusion services continues to increase and we are thrilled to open new locations to meet the needs of our patients. Now in 25 states, we will continue to partner with practitioners, physicians and payors to provide superior home infusion services with clinical excellence.” 

 “This transaction supports our strategy to focus on serving the specialty infusion market,” said Trish Lacavich, vice president and general manager, Coram. “We’ll continue to be a leading provider of specialty infusion services, enteral nutrition, and nursing support for patients on specialty medications in these markets as well as nationwide.” 

 KabaFusion has pioneered patient-focused home infusion services with deep clinical expertise in intravenous immunoglobulin (IVIG) therapies. This acquisition nearly doubles KabaFusion’s footprint of home infusion pharmacies. With this agreement, KabaFusion will enter new strategic markets in Minnesota, Ohio and Tennessee, and will extend the company’s existing footprint in California, Florida, New York, Texas, Virginia and others. KabaFusion is licensed to serve patients in 44 states with a comprehensive offering of acute, chronic and enteral therapies. 

KabaFusion’s clinician-led management team will continue to lead the business. KabaFusion is a member of Pritzker Private Capital’s family of companies. Terms of the transaction were not disclosed. 

About KabaFusion

 KabaFusion was founded by Dr. Sohail Masood, Pharm D., in 2010 and operates 24 home infusion specialty pharmacies strategically located in California, Alabama, Arkansas, Florida, Illinois, Indiana, Kentucky, Massachusetts, Michigan, New Jersey, New York, North Carolina, Pennsylvania, Texas, and Virginia. KabaFusion is guided by a commitment to positive clinical outcomes and excellence in specialty acute and chronic therapies including intravenous immunoglobulin (IVIG). The company is dedicated to working proactively with patients, healthcare practitioners and payors to provide comprehensive support before, during and after treatment. For more information, visit Kabafusion.com. 

 About Pritzker Private Capital 

 Pritzker Private Capital partners with middle-market companies based in North America with leading positions in the manufactured products and services sectors. The firm’s differentiated, long-duration capital base allows for efficient decision-making, broad flexibility with transaction structure and investment horizon, and alignment with all stakeholders. Pritzker Private Capital builds businesses for the long term and is an ideal partner for entrepreneur- and family-owned companies. Pritzker Private 

Capital is a signatory to the United Nations Principles for Responsible Investment (PRI). For more information, visit PPCPartners.com.